Oral Abstract Session:
48. Late Breaker Oral Abstracts: HIV and Antibiotic Trials
Thursday, October 4, 2018: 10:30 AM-11:45 AM
Room: S 151-153


Moderators:  Monica Gandhi, MD, MPH, Division of HIV, Infectious Diseases and Global Medicine, UCSF and Jodie Dionne-Odom, MD, 703 19th Street South

Presentations:
10:30 AM
LB1
Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
Chloe Orkin, MBBCh; Kathleen Squires, MD; Jean-Michel Molina, MD; Paul Sax, MD; Wingwai Wong, MD; Otto Sussmann, MD; Gina Lin, MS; Sushma Kumar, PhD; George Hanna, MD; Carey Hwang, MD, PhD; Elizabeth Martin, DO, MPH; Hedy Teppler, MD
10:40 AM
LB2
Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
Princy Kumar, M.D.; Margaret Johnson, MD, FRCP; Jean-Michel Molina, MD; Giuliano Rizzardini, MD; Pedro Cahn, MD, PhD; Markus Bickel, MD; Josep Mallolas, MD; Yan Zhou, PhD; Cristiana Morais, PhD; Sushma Kumar, PhD; Peter Sklar, MD, MPH; George J. Hanna, MD; Carey Hwang, MD, PhD; Wayne Greaves, MD
10:50 AM
LB3
Daptomycin plus Fosfomycin versus Daptomycin Monotherapy for Methicillin-resistant Staphylococcus aureus Bacteremia. A Multicenter, Randomized, Clinical Trial
Miquel Pujol, MD, PhD; Jose-Maria Miro, MD, PhD; Evelyn Shaw, MD, PhD; Jose Maria Aguado, MD, PhD; Rafael San-Juan Garrido, MD, PhD; Mireia Puig, MD, PhD; Carle Pigrau, MD, PhD; Esther Calbo, MD, PhD; Jose Miguel Montejo, MD, PhD; Regino Rodriguez, MD; Maria Jose Garcia-Pais, MD; Vicente Pintado, MD, PhD; Rosa Escudero, MD; Joaquin Lopez-Contreras, MD, PhD; Laura Morata, MD; Milagro Montero, MD, PhD; Marta Andres, MD; Juan Pasquau, MD, PhD; Belen Padilla, MD, PhD; Javier Murillas, MD, PhD; Alfredo Jover, MD, PhD; Luis Eduardo Lopez-Cortes, MD, PhD; Graciano Garcia-Pardo, MD; Oriol Gasch, MD, PhD; Sebastian Videla, MD, PhD; Cristian Tebe, MSc; Natalia Pallares, MSc; Pilar Hereu, MD, PhD; Mireia Sanllorente, MSc; Maria Angeles Dominguez, MD, PhD; Jordi Camara, MD; Ariadna Padulles, MD, PhD; Jordi Carratala, MD, PhD
11:00 AM
LB4
A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs ABC/DTG/3TC in Treatment-Naïve Adults at Week 96
David A. Wohl, MD; Yazdan Yazdanpanah, MD; Axel Baumgarten, MD; Amanda Clarke, M.D.; Melanie Thompson, MD; Cynthia Brinson, M.D.; Debbie Hagins, MD; Moti Ramgopal, MD, FACP, FIDSA; Andrea Antinori, MD; Xuelian Wei, PhD; Kirsten White, PhD; Sean Collins, MD; Andrew Cheng, MD PhD; Erin Quirk, MD; Hal Martin, MD, MPH
11:10 AM
LB5
Safety of In Utero Antiretroviral (ARV) Exposure: Neurologic Outcomes in HIV-Exposed, Uninfected Children
Claudia S. Crowell, MD MPH; Paige Williams, PhD; Cenk Yildirim, MS; Russell Van Dyke, MD; Renee Smith, PhD; Ellen G. Chadwick, MD; George Seage, ScD; Rohan Hazra, MD
11:20 AM
LB6
Oral Lefamulin Is Safe and Effective in the Treatment of Adults with Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
Elizabeth Alexander, MD; Lisa Goldberg, MS; Anita Das, PhD; Gregory J. Moran, MD; Christian Sandrock, MD; Leanne B. Gasink, MD; Patricia Spera, PhD; Carolyn Sweeney, BS; Susanne Paukner, PhD; Wolfgang W. Wicha, MS; Jennifer Schranz, MD

CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.